Department of Internal Medicine, University Hospital Center Zagreb, Zagreb, Croatia.
Dental Research Center, Mashhad Dental School, Mashhad University of Medical Sciences, Mashhad, Iran.
Curr Med Chem. 2024;31(39):6429-6435. doi: 10.2174/0929867331666230809100021.
Proprotein convertase subtilisin/Kexin type 9 (PCSK9) inhibitors are FDA-approved drugs recommended for high-risk patients with LDL-cholesterol (LDL-c) levels ≥ 70 mg/dl. Several studies have also investigated the relationship between PCSK9 and periodontitis. Specifically, studies have investigated the association between periodontitis and periodontal PCSK9 levels in humans, and periodontium status in PCSK9-knockout versus wild-type mice. While a positive association between periodontitis and periodontal PCSK9 levels has been noted, the findings on the comparison of periodontium status between PCSK9-knockout and wild-type mice have been inconsistent. Different methodologies among these studies may explain this discrepancy. Future experimental studies on the impact of pharmacological PCSK9 inhibition on periodontal status as well as observational studies comparing periodontium status between patients receiving PCSK9 inhibitors and those receiving other lipid-lowering drugs will shed light on the role of PCSK9 in periodontal health and disease.
前蛋白转化酶枯草溶菌素 9（PCSK9）抑制剂是美国食品药品监督管理局批准的药物，推荐用于 LDL-胆固醇（LDL-c）水平≥70mg/dl 的高危患者。几项研究还探讨了 PCSK9 与牙周炎之间的关系。具体而言，研究调查了人类牙周炎与牙周 PCSK9 水平之间的关系，以及 PCSK9 敲除与野生型小鼠的牙周状况。虽然已经注意到牙周炎与牙周 PCSK9 水平之间存在正相关，但关于 PCSK9 敲除与野生型小鼠牙周状况比较的研究结果并不一致。这些研究之间的不同方法学可能解释了这一差异。未来关于药物性 PCSK9 抑制对牙周状况影响的实验研究以及比较接受 PCSK9 抑制剂治疗和接受其他降脂药物治疗的患者牙周状况的观察性研究将阐明 PCSK9 在牙周健康和疾病中的作用。
